Healthcare
Oruka Therapeutics, Inc.(ORKA)
Live Price
Offline$72.34
+2.06% today
Window Change
+23.59%
Window
May 29, 2026 โ Jun 18, 2026
- Market Cap
- $2.34B
- Revenue Growth
- 0.0%
- EPS Growth
- +53.7%
- Dividend Yield
- 0.0%
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 15 bars ยท May 29, 2026 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Oruka Therapeutics, Inc. (ORKA) is a Healthcare stock with a market cap of $2.34B and listed on NASDAQ. The stock last traded around $72.34 and up 23.6% across the available one-year price window (May 29, 2026 โ Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +53.7%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +53.7%, free cash flow -52.4% with operating margin 0.0% and ROIC -25.8%. Stock Foundry combines ORKA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 13, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +53.7%, while operating margin sits near 0.0%.
Benchmark Edge
ORKA vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
ORKA
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
ORKA Max Drawdown
-6.01%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for ORKA and SPY.
Company Overview
Oruka Therapeutics, Inc.
NASDAQ Global Market
Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.
- Leadership
- Lawrence Otto Klein
- IPO Date
- Aug 8, 1997
- Employees
- 28
- Street Address
- 221 Crescent Street Building 23, Suite 105
- Mailing
- Menlo Park, MA
- Region
- Menlo Park, MA, US
- Reporting Currency
- USD
- Investor Line
- 203-554-7604
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 7.2
Growth
- Revenue
- 0.0%
- EPS
- +53.7%
- Free Cash Flow
- -52.4%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -25.3%
- ROIC
- -25.8%
Balance Sheet
- Debt/Equity
- 0.00
- Current Ratio
- 22.37
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.